INNOVATEChina2022 is launched in partnership with Boehringer Ingelheim


  • INNOVATEChina is the flagship business innovation competition from CEIBS MBA.
  • This year’s theme will be “Globalising Chinese healthcare innovations”.
  • Boehringer Ingelheim has decided join IC22 as industrial partner.
  • The top team will receive USD 10,000 in prize money.


Shanghai, China, 15 June 2022 – INNOVATEChina2022, the flagship business innovation competition from the China Europe International Business School (CEIBS), has officially been launched in collaboration with Boehringer Ingelheim China as Industry Partner. Event registration will officially open on 1 August 2022 and the final competition date will be 16-17 December 2022. The top three teams will respectively win USD 10,000, USD 5,000 and USD 3,000 in prize money.

This year, with the theme “Globalising Chinese healthcare innovations”, INNOVATEChina2022 shines the spotlight on one of the most relevant and dynamic industries in China and the world today – healthcare. INNOVATEChina2022 will offer a rich and comprehensive program, including lectures, company roadshows, forums, mentoring and coaching sessions, to provide an intellectually stimulating platform for entrepreneurial and dynamic individuals to:

  • Learn about the recent innovations in world’s second-largest healthcare market;
  • Take these insights to their own local contexts to benefit patients and society;
  • Validate their business ideas with invaluable support and mentoring from healthcare industry leaders in China and globally

In line with CEIBS MBA’s ethos of ‘China Depth, Global Breadth’, the competition will also enable international and Chinese teams to leverage China-based innovations for global applications. The deep industry expertise and knowledge of Boehringer Ingelheim China and McKinsey China, along with the commitment, energy and professionalism of the Organising Team, will drive the success of this trademark CEIBS MBA event.

The 2022 Core Organising Team comprises six MBA 2023 students, with Karen Xi as president; Edward Tang as vice-president; as well as Adam Jin, David Cheng, Fred Hu and Rita Qiu as core members. Daniel Wang, Head of the CEIBS eLab, is the CEIBS MBA Office Representative overseeing the event.


INNOVATEChina 2019 stage show

First launched in 2008, INNOVATEChina is one of the largest business innovation competitions held globally. Every year, dozens of teams from the world’s leading business schools and educational institutions compete to win this prestigious competition. INNOVATEChina provides an intellectually stimulating platform for entrepreneurial and dynamic individuals to validate their most innovative business ideas and receive invaluable mentoring from top faculty members and industry leaders. For more information, please visit

 About China Europe International Business School (CEIBS)

China Europe International Business School (CEIBS) was co-founded by the Chinese government and European Union (EU) in 1994. CEIBS is committed to educating responsible leaders versed in ‘China Depth, Global Breadth’ in line with its motto of ‘Conscientiousness, Innovation and Excellence’. The 16-month CEIBS MBA programme was ranked #7 in the world and #1 in Asia by the Financial Times in 2021. CEIBS has campuses in Shanghai, Beijing and Shenzhen in China; Accra in Ghana; and Zurich in Switzerland. For more information, please visit

About Boehringer Ingelheim China

Boehringer Ingelheim is one of the top biopharmaceutical companies in the world. Headquartered in Ingelheim Germany, the company operates presently with a total of more than 52,000 employees. Making new and better medicines for humans and animals is at the heart of what we do.

Boehringer Ingelheim China is headquartered in Shanghai with more than 4,000 employees. The major business focuses of Boehringer Ingelheim China includes human pharma, animal health and biopharmaceuticals. In recent years, the company has achieved continuous growth, outperformed the market average.

Boehringer Ingelheim China has been certified as “China Top Employer” during 2014 to 2022. China is one of the company’s most important strategic markets. China’s needs have been incorporated into the company’s global R&D strategy. The company aims to bring more and better innovative products earlier to the Chinese patients, contribute to the high-quality development of China’s healthcare industry, and comprehensively improve the health of human and animals. For more information, please visit: or


To reach the Organising Team of INNOVATEChina2022, please email

Leave a Reply

%d bloggers like this: